Novo Nordisk's stock price rose 7% as sales of its weight loss drug Wegovy were positive in the first week of launch

阿斯達克財經網
2026.01.16 17:54

諾和諾德 (NVO.US) 週五股價上升逾 7%，該公司用於治療肥胖症的新型 GLP-1 藥物 Wegovy 在美國上市初期取得正面結果。

分析師在報告中稱，諾和諾德新減肥藥物上市首周共開出約 4,290 張處方，其中大部分是初始劑量；相較之下，禮來 (LLY.US) 旗下減肥藥 Zepbound 在上市首周的處方量約為 1,900 張。該藥於去年 12 月底獲得批准，並於 1 月 5 日正式上市。

Source: 阿斯達克財經網 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.